Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

BioNTech SE
Next earnings Aug 4, 2026 · consensus $-1.97 EPS, $216M rev
Mixed signals in the latest filings.
BioNTech SE shows limited reported revenue.
Sources: SEC EDGAR (CIK 0001776985, latest 6-K filed 2026-06-08) · EODHD · as of 6/22/2026, 12:03:06 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
€15/mo · cancel anytime
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1482 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Last 90 days: 0 open-market buys · 1 sale
| 2026-04-22 | Poetting Sierk Chief Operating Officer | Sell | 50.0K @ $110.56 | $5.53M |
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.